Latta Applauds FDA Approval of First New Sunscreen Ingredient in More Than 20 Years

Today, Congressman Bob Latta (OH-5) released the following statement after the Food and Drug Administration (FDA) announced that bemotrizinol has been added to the list of permitted sunscreen active ingredients. Bemotrizinol is the first new active ingredient added to the over-the-counter (OTC) sunscreen monograph in more than 20 years.

"FDA's announcement in adding bemotrizinol to a list of permitted sunscreen active ingredients is a significant step forward in expanding access to innovative sunscreen products for American consumers. For too long, the FDA's approval process prevented new sunscreen ingredients that are widely used around the world from becoming available in the United States. The reforms included in the OMUFA Act helped modernize the review process, and this decision demonstrates the importance of continuing to advance innovation while ensuring consumers have access to safe and effective products," said Latta.

In July 2025, Congressman Latta introduced the bipartisan Over-the-Counter Monograph Drug User Fee Amendments (OMUFA) to reauthorize the Over-the-Counter Monograph User Fee Program, which helps provide Americans with access to safe and effective over-the-counter medicines. The legislation was signed into law in November 2025 as part of a Continuing Resolution.

A member of the House Energy and Commerce Committee, Congressman Latta has consistently advocated for improving the FDA's review process for sunscreen ingredients. During a recent committee hearing, he highlighted the need to modernize the agency's sunscreen approval framework and ensure Americans have access to the latest sunscreen innovations.